ACADIA Pharmaceuticals Inc (ACAD)

30.28
0.19 0.63
NASDAQ : Health Care
Prev Close 30.09
Open 29.98
Day Low/High 29.78 / 30.57
52 Wk Low/High 16.64 / 50.40
Volume 231.16K
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 122.05M
Market Cap 3.54B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

3 Fearless Predictions for the Second Half

3 Fearless Predictions for the Second Half

The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

Here are the activist investor's next potential targets.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference On May 16, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce First Quarter 2017 Financial Results On May 9, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Doug Kass shares his thoughts on Twitter, Apple and Alphabet.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At Needham & Company's 16th Annual Healthcare Conference On April 5, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Cowen And Company 37th Annual Health Care Conference On March 6, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.